Dr Kylie Mason is a Clinical Haematologist and translational researcher with a joint appointment at The Royal Melbourne Hospital and The University of Melbourne. She is the lead clinician for the Haemoglobinopathy program and coordinates a team with in and out patient management of sickle cell disease and thalassaemia. Additionally she has an interest in malignant haematology, is the lead investigator on a number of clinical lymphoma trials and is the lead of the Late Effects and Survivorship team. Additionally she represents haematology on the economics subcommittee of the national pharmaceutic benefits advisory committee.
Abstracts this author is presenting: